<DOC>
	<DOCNO>NCT01853852</DOCNO>
	<brief_summary>GR181413A/AT1001 ( migalastat hydrochloride ) low molecular weight iminosugar , analog terminal galactose group cleave substrate GL-3 . This compound research developed drug treatment Fabry disease . This study , MGM115806 , first administration GR181413A/AT1001 Japanese subject investigate safety , tolerability pharmacokinetics single oral dos healthy Japanese adult subject . Approximately 12 subject receive three treatment 50 , 150 450 mg GR181413A/AT1001 fast condition plus placebo dose ascend crossover design . Serial pharmacokinetic sample collect safety assessment perform follow dose . The pharmacokinetics dose proportionality GR181413A/AT1001 single oral dos GR181413A/AT1001 dose level 50 , 150 450 mg fast condition assess .</brief_summary>
	<brief_title>A Phase I , Randomized , Single-Blind , Four-Period Cross-Over , Placebo-Controlled , Dose-Escalation Study Evaluate Safety Pharmacokinetics Single Oral Doses GR181413A/AT1001 Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>1 . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . 2 . Male female 20 55 year age inclusive , time signing informed consent . 3 . A female subject eligible participate : Nonchildbearing potential define premenopausal female . 4 . Male subject female partner childbearing potential must agree use one contraception method . This criterion must follow time first dose study medication 5 terminal halflives postlast dose . 5 . Body weight &gt; =50 kg BMI within range 18.5 29.0 kg/m2 ( inclusive ) . 6 . Capable give write informed consent , include compliance requirement restriction list consent form . 7 . AST , ALT , alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 8 . Single QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . 9 . Japanese define born Japan , four ethnic Japanese grandparent , hold Japanese passport identity paper able speak Japanese . Japanese subject also live outside Japan le 10 year . 1 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . 2 . A positive prestudy drug/alcohol screen . 3 . A positive test HIV antibody . 4 . History regular alcohol consumption within 6 month study 5 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever long ) . 6 . Exposure four new chemical entity within 12 month prior first dose day . 7 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St Johns Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . 8 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . 9 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 10 . History regular use tobacco nicotinecontaining product within 6 month prior screen . 11 . Pregnant female determine positive serum urine hCG test screen prior dosing . 12 . Lactating female . 13 . Unwillingness inability follow procedure outline protocol . 14 . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>